No abstract available
MeSH terms
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Carcinoma, Hepatocellular / pathology
-
Carcinoma, Hepatocellular / therapy*
-
Chemoembolization, Therapeutic / adverse effects
-
Chemoembolization, Therapeutic / methods*
-
Clinical Decision-Making
-
Clinical Trials as Topic
-
Combined Modality Therapy
-
Disease Management
-
Humans
-
Liver Neoplasms / pathology
-
Liver Neoplasms / therapy*
-
Neoplasm Staging
-
Niacinamide / administration & dosage
-
Niacinamide / adverse effects
-
Niacinamide / analogs & derivatives*
-
Niacinamide / therapeutic use
-
Phenylurea Compounds / administration & dosage
-
Phenylurea Compounds / adverse effects
-
Phenylurea Compounds / therapeutic use*
-
Protein Kinase Inhibitors / administration & dosage
-
Protein Kinase Inhibitors / adverse effects
-
Protein Kinase Inhibitors / therapeutic use*
-
Sorafenib
-
Treatment Outcome
Substances
-
Antineoplastic Agents
-
Phenylurea Compounds
-
Protein Kinase Inhibitors
-
Niacinamide
-
Sorafenib